Dynamic competition in pharmaceuticals
Tóm tắt
This paper investigates patterns of industrial dynamics and competition in the pharmaceutical industry, with particular reference to the consequences of patent expiry in different countries. We focus on the competition at the level of single chemical entities, distinguishing between original brands and generic products. Quarterly data, spanning from July 1987 to December 1998, on sales of pharmaceutical products in four countries (USA, UK, Germany, and France) constitute the basis of our analysis. All the products containing major molecules whose patent expiration date lies between 1986 and 1996 are included in our sample. We show how diffusion of generics is linked to the characteristics of the market and investigate how price dynamics of original products are affected by generic competition. Our empirical investigation shows that the dynamics of drug prices and the competition by generic drugs vary significantly across countries. This heterogeneity notwithstanding, a clear distinction seems to emerge. On the one hand, systems that rely on market-based competition in pharmaceuticals promote a clear distinction between firms that act as innovators and firms that act as imitators after patent expiry. Here, original products enjoy premium prices and exclusivity profits under patent protection, and face fierce price competition after patent expiry. On the other hand, in systems that rely on administered prices, penetration by generic drugs tends to be rather limited. Its descriptive and preliminary nature notwithstanding, our analysis seems to have relevant implications at different levels of generality, especially for Europe.
Tài liệu tham khảo
Ahn S (2002) Competition, innovation, and productivity growth: a review of theory and evidence. OECD Economics Department, Working Paper 317
Ashiya M (2000) Weak entrants are welcome. Int J Ind Organi 18:975–984
Bae JP (1997) Drug patent expirations and the speed of generic entry. Health Serv Res 32:187–101
Blundell R, Griffith R, Van Reenen J (1995) Dynamic count data models of technological innovation. Econ J 105:333–344
Caves RE, Whinston MD, Hurwitz MA (1991) Patent expiration, entry and competition in the US pharmaceutical industry. Brookings Papers on Economic Activity. Microeconomics 1991:1–48
Ching ATT (2000) Dynamic equilibrium in the prescription drug market after patent expiration. PhD Dissertation, University of Minnesota
Cohen W, Levin R (1989) Empirical studies of innovation and market structure. In: R Schmalensee, J Willing (eds). The handbook of industrial organization, I. North Holland, Amsterdam, pp 1059–1107
Danzon PM, Chao LW (2000) Cross-national price differences for pharmaceuticals: how large and why? J Health Econ 19:159–195
Eswaran M (1994) Licensees as entry barriers. Can J Econ 27:673–688
Gambardella A, Orsenigo L, Pammolli F (2001) Global competitiveness in pharmaceuticals. A European perspective. Directorate General Enterprise, European Commission, Brussels
Garattini L, Tediosi F (2000) A comparative analysis of generics markets in five European countries. Health Pol 51:149–162
Grabowski HG, Vernon JM (1992) Brand loyalty, entry and price competition in the pharmaceuticals after the 1984 Drug Act. J Law Econ 35:331–350
Grabowski HG, Vernon JM (1996) Longer patents for increased generic competition in the US. Pharmacoeconomics 10:110–123
Hollis A (2003) The anti-competitive effects of brand-controlled ‘Pseudo-Generics’ in the Canadian pharmaceutical market. Can Public Policy 29:21–31
Hudson J (2000) Generic take-up in the pharmaceutical market following patent expiry. A multi-country study. Int Rev Law Econ 20:205–221
Hurwitz MA, Caves RE (1988) Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals. J Law Econ 31:299–320
Jacobzone S (2000) Pharmaceutical policies in OECD countries: reconciling social and industrial goals. OECD Labor Market and Social Policy Occasional Papers, 40
López-Casanovas G, Jönsson B (2001) Reference pricing and pharmaceutical policy: perspectives on economics and innovation. Kluwer, Dordrecht
Pammolli F, Magazzini L, Orsenigo L, (2002) The intensity of competition after patent expiry in pharmaceuticals: a cross-country analysis. Rev Econ Ind 99:107–132
Mossialos E (1997) Citizens’ view on health systems in the 15 member states of the European Union. Health Econ 6:109–116
NERA (1998) Policy relating to generic medicines in the OECD. Report for the European Commission, Brussels
Scott Morton FM (1997) Entry decision in the generic pharmaceutical industry. NBER Working Paper 6190
Suh DC (1993) Effect of multiple source entry on price competition after patent expiration in the pharmaceutical industry. PhD Dissertation, University of Minnesota
Yi S (1999) Entry, licensing and research joint ventures. Int J Ind Organi 17:1–24